Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial

PURPOSE: (18)F-Labelled fluorodeoxyglucose (FDG) can detect early changes in tumour metabolism and may be a useful quantitative imaging biomarker (QIB) for prediction of disease stabilization, response and duration of progression-free survival (PFS). Standardization of imaging procedures is a prereq...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur J Nucl Med Mol Imaging
Autores principales: Hristova, Ivalina, Boellaard, Ronald, Vogel, Wouter, Mottaghy, Felix, Marreaud, Sandrine, Collette, Sandra, Schöffski, Patrick, Sanfilippo, Roberta, Dewji, Raz, van der Graaf, Winette, Oyen, Wim J. G.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4382532/
https://ncbi.nlm.nih.gov/pubmed/25711176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-015-3002-0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares